文献速递主动脉疾病

基于病种的腹主动脉瘤腔内修复术成本降低策略

Episode-based cost reduction for endovascular aneurysm repair.
PubMed 文献 · J Vasc Surg · 2018-06-28

在高容量学术医疗中心分析腹主动脉瘤腔内修复术(EVAR)相关成本,针对植入物、房间使用和CT扫描实施干预,比较干预前141例与干预后47例的直接成本。结果显示器械成本降低30.8%、影像成本降低92.9%、术前房间使用率从35.4%降至17.0%,且未对术后中位住院时间产生显著影响;结论认为针对性降本措施可在不损害质量或患者可及性的前提下有效降低费用。

要点

  • 针对性成本控制措施可使EVAR每例器械成本降低30.8%。
  • 影像成本降低92.9%,其中后处理成本降低99.0%。
  • 术前房间使用率从35.4%降至17.0%,术后中位住院时间无显著变化。

核心结论

  • EVAR相关过高成本威胁其在医疗机构中的可持续性;针对性降本措施可在不损害质量或限制患者可及性的前提下有效降低费用。

研究设计与样本

  • 2015年6月至2016年2月在高容量学术医疗中心分析EVAR实践,识别、排序并降低操作相关成本,比较干预前(2013年9月至2015年5月)141例与干预后(2016年3月至2017年1月)47例EVAR的每例患者医院直接成本。

主要发现

  • 基于血管外科学会EVAR成本示范项目数据,确定植入器械成本高于同行机构,实施新采购策略后每例器械成本在干预前与干预后期间降低30.8%。
  • 修改诊疗路径以减少索引住院期间CT扫描的使用和成本后,每例影像成本较基线降低92.9%(P < .001),其中后处理成本降低99.0%(P = .001)。
  • 实施诊疗路径以减少远距离患者在手术前一日术前房间使用后,使用率从干预前35.4%降至干预后17.0%(P = .021),术后中位住院时间干预前为2天(四分位距1-11天)、干预后为2天(四分位距1-7天),差异无统计学显著(P = .185)。
  • 作为全院性举措,药物成本亦降低38.2%(P < .001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Effective strategies to reduce costs associated with endovascular aneurysm repair (EVAR) remain elusive for many medical centers. In this study, targeted interventions to reduce inpatient EVAR costs were identified and implemented. METHODS: From June 2015 to February 2016, we analyzed the EVAR practice at a high-volume academic medical center to identify, to rank, and ultimately to reduce procedure-related costs. In this analysis, per-patient direct costs to the hospital were compared before (September 2013-May 2015) and after (March 2016-January 2017) interventions were implemented. Improvement efforts concentrated on three categories that accounted for a majority of costs: implants, rooming costs, and computed tomography scans performed during the index hospitalization. RESULTS: Costs were compared between 141 EVAR procedures before implementation (PRE period) and 47 EVAR procedures after implementation (POST period). Based on data obtained through the Society for Vascular Surgery EVAR Cost Demonstration Project, it was determined that implantable device costs were higher than those at peer institutions. New purchasing strategies were implemented, resulting in a 30.8% decrease in per-case device costs between the PRE and POST periods. Care pathways were modified to reduce use of and costs for computed tomography scans obtained during the index hospitalization. Compared with baseline, per-case imaging costs decreased by 92.9% (P < .001), including a 99.0% (P = .001) reduction in postprocessing costs. Care pathways were also implemented to reduce preprocedural rooming for patients traveling long distances the day before surgery, resulting in a 50% decrease in utilization rate (35.4% PRE to 17.0% POST; P = .021), without having a significant impact on median postprocedural length of stay (PRE, 2 days [interquartile range, 1-11 days]; POST, 2 days [1-7 days]; P = .185). Medication costs also decreased by 38.2% (P < .001) as a hospital-wide effort. CONCLUSIONS: Excessive costs associated with EVAR threaten the sustainability of these procedures in health care organizations. Targeted cost reduction efforts can effectively reduce expenses without compromising quality or limiting patients' access.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Itoga NK, Tang N, Patterson D, et al. Episode-based cost reduction for endovascular aneurysm repair. J Vasc Surg. 2018. PMID: 30185384. doi:10.1016/j.jvs.2018.04.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。